Genmab — Januar 2020
-
M.h.t. det berømte 3 mia tal så skal der, efter mine beregninger, være gået noget HELT galt med tallene i ROW, hvis vi ikke når det. Eller der skal være givet en større rabat et sted. Med en behersket stigning dag/dag i US på 3,4 pct. (og 14 pct rabat) skal ROW være under 380 i 4 kvt. for ikke at nå de 3 mia. Det er, i min optik, ret urealistisk. Men shit happens, som man siger.
Jeg tror på, at vi lander pænt, indtil det modsatte er bevist. -
Novel Therapeutics for Recurrent Cervical Cancer: https://link.springer.com/article/10.1007%2Fs40265-019-01249-z in full https://sci-hub.tw/https://link.springer.com/article/10.1007%2Fs40265-019-01249-z
-
-
clues into Gilead's M&A strategy https://www.fiercepharma.com/pharma/want-clues-into-gilead-s-m-a-strategy-check-out-last-year-s-galapagos-deal
-
Ja, det er sjovt - det er der nogen der hårdnakket benægter kan være tilfældet. Fordi det åbenbart ikke MÅ VÆRE rigtigt. Ledelsens argumenter omkring øget synlighed og bedre adgang til bredere og mere risiovillig investormasse, skal i hvert fald ikke tages for gode varer!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind